Clinical Trial Update: Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA [Phase 2]

View source ↗

Summary

This entry notes a Phase 2 clinical trial of Romiplostim N01 for refractory aplastic anemia induced by chemoradiotherapy, with status not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Romiplostim N01 (romiplostim)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Aplastic Anemia | Phase 2 | Status: NOT_YET_RECRUITING